Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
St. Jude Children's Research Hospital
Shanghai Jiao Tong University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
China Medical University Hospital
University Health Network, Toronto
Chang Gung Memorial Hospital
M.D. Anderson Cancer Center
University of Kentucky
University of Illinois at Chicago